News | July 08, 2009

Tissue Regeneration Used to Rebuild Patients’ Heart Structures

July 8, 2009 - Marc Gerdisch, M.D., director of cardiothoracic surgery at the St. Francis Heart Center and a partner at Cardiac Surgery Associates, is using the CorMatrix Extracellular Matrix (ECM) to modify and repair cardiac structures, allowing heart tissue to regrow inside the beating hearts of heart surgery patients. The CorMatrix ECM is a unique biomaterial that harnesses the body’s innate ability to repair damaged heart tissue. Over time, it is replaced by the patient’s own tissue.

“The use of this biomaterial is a major advancement in cardiac surgery and allows us to provide our patients with restoration of normal anatomic structures. It opens the door to a new level of cardiac tissue reconstruction,” said Dr. Gerdisch.

In August 2007, Dr. Gerdisch, who specializes in complex heart valve surgery, became the first in the world to apply this technology inside the heart, repairing a congenital defect.

“Similar uses of the ECM followed at our and other institutions,” reported Dr. Gerdisch, who is codirector of the St. Francis Midwest Heart Valve Center. “Then, in March 2008, we performed the first enlargement of the path blood follows as it exits in the heart using the CorMatrix ECM, in lieu of a prosthetic device, for a patient undergoing valve surgery.”

The first mitral valve reconstruction using CorMatrix occurred at St. Francis Heart Center in October of 2008. A patient’s valve had developed large defects because of infection. CorMatrix patches restored the valve to normal function and helped avoid a replacement.

“We have been able to make similar repairs for other patients since,” added Gerdisch.

The CorMatrix ECM is derived from porcine small intestines and is processed in a way that removes all cells, leaving the complex structural matrix intact. Once surgically implanted, it serves as a scaffold, allowing the patient’s cells to infiltrate and ultimately replace the ECM scaffold.

While the patient continues to heal, the matrix is gradually replaced as the body reinforces and remodels the tissue. In the past, tissue replacement has been limited by options for implantation.

Animal tissue implants are subject to calcium deposition and hardening because the body recognizes them as foreign. Synthetic material lacks the performance characteristics of tissue and causes an inflammatory response. ECM, however, leads to growth of functional tissue where scarring would normally be expected.

For more information: www.cardiactissuerepair.net

Related Content

First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
Overlay Init